Lipid Management Utilizing PCSK9 Inhibitors

Deepak R. Talreja, MD, discusses the current advances in lipidology. Here he discusses lipid management that utilizes PCSK9 inhibitors, how these effect cholesterol, how to determine if your patient is a candidate for this type of treatment, and what complications one might expect from this treatment. 


February 16, 2018

Created by


Related Presenters

Deepak Talreja, MD, FACC

Deepak Talreja, MD, FACC

Sentara Cardiology Specialists

Dr. Talreja is an experienced cardiologist with Sentara Cardiology Specialists in Virginia Beach and Chesapeake. He has extensive training and expertise in complex coronary interventions, structural heart disease, echocardiography, transesophageal...

View full profile